CE

Clara Estol

Investor @PicusCapital | MIT Sloan | Ex-McKinsey

New York, New York

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Investor

    2024

2022 - 2023

  • Venture Fellow

    2022 - 2023

    Sourced and conducted due diligence on global fintech targets, developed Embedded Finance investment thesis, and pioneered QED's inaugural portfolio playbook to support entrepreneurs.

  • Summer Associate

    2022 - 2022

    Pre-seed to Series C investment within the Health Tech, Cyber Tech, and Climate Tech sectors.

2019 - 2021

  • Chief of Staff ank

    2019 - 2021

    Developed and implemented strategies for the launch of payment products (P2P, QR, credit card); achieved 1M downloads within five months. I worked with C-level executives on budgeting, annual planning and long-term resource allocation.

2017 - 2019

  • Business Analyst

    2017 - 2019

    Worked in projects in the the Financial Services, Insurance, CPG, Oil&Gas, and Energy sectors. - Led post-acquisition integration of Argentina's largest Oil & Gas company with a leading commodity trading firm, facilitating seamless transfer of assets valued at +$125M - Established and implemented a cost-saving strategy for a global CPG company with 800 full-time employees; resulting in a $60M impact - Executed a commercial transformation for a leading Insurance company attaining a $40M impact. - Designed and implemented an agile transformation for a leading bank including the set-up of new business units (300+ FTEs)

2019 - 2019

  • Co-Founder & CEO

    2019 - 2019

    Founded IZZY EAT, a PWA streamlining restaurant-customer interaction. The platform enabled real-time order placement and payment through a QR code scan; 5 main Argentinean restaurant chains with +500 restaurants signed up for the pilot and the MVP was tested in 2 of them.

2015 - 2015

  • Project Lead

    2015 - 2015

    Developed a Business Plan for a clinical research to be carried out for Ashkenazi women in Argentina (One in 40 Ashkenazi Jewish women has a BRCA gene mutation. Mutations in BRCA genes raise a person's risk for getting breast cancer and/or ovarian cancer).